Galmed Pharmaceuticals
GLMD
34 hedge funds and large institutions have $50.9M invested in Galmed Pharmaceuticals in 2019 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 12 increasing their positions, 10 reducing their positions, and 3 closing their positions.
20% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 10
0.01% more ownership
Funds ownership: 0.2% → 0.2% (+0.01%)
0% more funds holding
Funds holding: 34 → 34 (0)
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
16% less capital invested
Capital invested by funds: $60.6M → $50.9M (-$9.66M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $74K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
II
Ibex Investors
Denver,
Colorado
|
+$1.06M |
| 2 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$605K |
| 3 |
PAM
Premier Asset Management
Chicago,
Illinois
|
+$558K |
| 4 |
RCG
Rock Creek Group
Washington,
District of Columbia
|
+$410K |
| 5 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
+$191K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$330K |
| 2 |
PAWC
P.A.W. Capital
Greenwich,
Connecticut
|
-$143K |
| 3 |
Goldman Sachs
New York
|
-$138K |
| 4 |
MIH
Meitav Investment House
Bene-Beraq,
Israel
|
-$103K |
| 5 |
FMBTD
First Midwest Bank Trust Division
Joliet,
Illinois
|
-$95.4K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
US Bancorp
Minneapolis,
Minnesota
| $14K | -$3.87K | -3 | -23% |
|
27
Bank of America
Charlotte,
North Carolina
| $11K | +$2.58K | +2 | +33% |
|
28
UBS Group
Zurich,
Switzerland
| $9K | +$9.03K | +7 | New |
|
29
Wells Fargo
San Francisco,
California
| $8K | -$14.2K | -11 | -65% |
|
|
FDCDDQ
30
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
| $7.35K | – | – | – |
|
|
II
31
Ibex Investors
Denver,
Colorado
| $5.93K | +$1.06M | +822 | +22% |
|
|
FHA
32
Flagship Harbor Advisors
Boston,
Massachusetts
| $2K | – | – | – |
|
|
RFA
33
Reilly Financial Advisors
La Mesa,
California
| $2K | – | – | – |
|
|
34
Goldman Sachs
New York
| – | -$138K | -94 | Closed |
|
|
SWM
35
SeaCrest Wealth Management
Purchase,
New York
| – | -$4K | -3 | Closed |
|
36
Simplex Trading
Chicago,
Illinois
| – | -$2.58K | -2 | Closed |
|
|
CG
37
Cutler Group
San Francisco,
California
| – | -$1.29K | -1 | -50% |
|
GLMD Hedge Fund Activity: Q2 2019 in Review
34 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Galmed Pharmaceuticals (GLMD) for Q2 2019, worth a combined $50.9M — down 16% from $60.6M a quarter earlier.
Fund positioning in GLMD was balanced in Q2 2019: 3 funds opened new positions, 3 closed out, 12 added to existing stakes and 10 trimmed.
The largest buyer was Ibex Investors, adding an estimated $1.06M. The largest seller was BVF Inc, cutting an estimated $330K.
- 34 institutional investors held Galmed Pharmaceuticals (GLMD) as of Q2 2019, unchanged from Q1 2019.
- Funds reported $50.9M of Galmed Pharmaceuticals stock for Q2 2019, down 16% quarter-over-quarter.
- 3 funds opened new Galmed Pharmaceuticals positions in Q2 2019 and 3 closed out, a net change of 0 holders.
- The largest Galmed Pharmaceuticals buyer in Q2 2019 was Ibex Investors, an estimated $1.06M added.
- The largest Galmed Pharmaceuticals seller in Q2 2019 was BVF Inc, an estimated $330K sold.
Based on aggregated 13F filings for Q2 2019.